101140 — InBioGen Co Balance Sheet
0.000.00%
- KR₩117bn
- KR₩112bn
- KR₩7bn
Annual balance sheet for InBioGen Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | ARS/A | ARS/A | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 79,035 | 23,152 | 9,290 | 6,089 | 5,716 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5,436 | 6,575 | 5,662 | 4,271 | 3,429 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 85,847 | 31,902 | 16,733 | 11,332 | 9,280 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1,118 | 4,361 | 3,691 | 2,595 | 1,186 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 96,881 | 274,475 | 144,284 | 145,704 | 162,730 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 18,133 | 77,775 | 36,362 | 2,114 | 2,117 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 18,975 | 96,452 | 37,400 | 2,621 | 2,894 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 77,906 | 178,023 | 106,884 | 143,083 | 159,837 |
Total Liabilities & Shareholders' Equity | 96,881 | 274,475 | 144,284 | 145,704 | 162,730 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |